Compare FNWD & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FNWD | TTRX |
|---|---|---|
| Founded | 1994 | 2015 |
| Country | United States | United States |
| Employees | N/A | 2 |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 147.7M | 174.9M |
| IPO Year | 1996 | N/A |
| Metric | FNWD | TTRX |
|---|---|---|
| Price | $36.65 | $7.29 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $37.50 | $8.00 |
| AVG Volume (30 Days) | 26.1K | ★ 54.4K |
| Earning Date | 04-28-2026 | 05-31-2026 |
| Dividend Yield | ★ 1.51% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.52 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $17.40 | N/A |
| Revenue Next Year | $5.44 | N/A |
| P/E Ratio | $69.33 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $26.46 | $2.57 |
| 52 Week High | $39.99 | $6.98 |
| Indicator | FNWD | TTRX |
|---|---|---|
| Relative Strength Index (RSI) | 73.90 | 73.24 |
| Support Level | $35.27 | $2.81 |
| Resistance Level | $38.99 | N/A |
| Average True Range (ATR) | 1.43 | 0.63 |
| MACD | 0.28 | 0.08 |
| Stochastic Oscillator | 79.36 | 97.42 |
Finward Bancorp is a bank holding company that engages in the provision of financial services. It offers products and services related to Personal Banking, Cash Management, Savings Account, ebanking, Wealth Management, and Insurance Services. It is engaged in the business of attracting deposits from the general public and the origination of loans, mostly upon the security of single-family residences and commercial real estate, construction loans, commercial business loans, and municipal loans. Geographically, the activities are carried out throughout the United States. The Company operates as a single reportable segment that derives its revenue mainly from the business of banking.
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.